Editas Medicine
Editas Medicine's revenue rose 25.4% to $40 million in fiscal 2025. Its operating margin was −394.9%, up from −777.2% a year earlier. Free cash flow was −$166 million. The diluted share count rose 7.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Editas Medicine does
Editas Medicine is a gene editing company. It uses CRISPR, a tool made of an enzyme and a guide molecule that finds a specific stretch of DNA and cuts it, to build medicines for serious genetic diseases. It says its platform includes two CRISPR enzymes, Cas9 and Cas12a, along with engineered forms of both and the key patents for them.
The company wants to lead in in vivo editing, where the medicine is injected or infused so the cells are edited inside the body. Its approach, called functional upregulation, edits regulatory DNA next to a gene to raise the output of a normal gene copy, without changing the protein itself. Its lead program, EDIT-401, is still in preclinical development, meaning it has not yet been tested in people.
Editas has no products approved for sale and has never earned revenue from product sales. It also works on a delivery system built from lipid nanoparticles, tiny fat-based particles that carry the editing tools into cells.
Its biggest risks, as it describes them
- It has lost money since it started and may never be profitable.
- It has no approved products, and most of its effort goes into EDIT-401, which is still preclinical.
- Gene editing is a relatively new technology, so the time, cost and chance of success are hard to predict.
- It will need substantial additional funding, which could dilute shareholders.
- Rules for genetic medicines have changed often and may keep changing.
Income statement
Editas Medicine lost money in fiscal 2025: a net loss of $160 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 500 | 344 | 323 | 270 | 147 |
| Debt incl. finance leases | — | — | 0 | 57 | 59 |
| Net debt (negative means net cash) | — | — | −323 | −212 | −88 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 0.0x | 0.4x | 2.1x |
| Interest coverage | — | — | — | — | −75.2x |
| Current ratio | 10.8x | 5.9x | 5.4x | 3.8x | 3.5x |
| Quick ratio | 10.8x | 5.9x | 5.4x | 3.8x | 3.5x |
Cash flow
Projections
Project Editas Medicine's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Editas Medicine reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 1 of 8 | 2 of 8 |
| Rule of 40 | 121.1% | −736.7% | −383.9% |
| Altman Z'' | −4.23 | −14.20 | −29.91 |
| Accruals ratio | −4.2% | −6.4% | 2.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | Fail | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | 1 of 8 | 2 of 8 |
Compare
Put Editas Medicine side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Editas Medicine | FY25 | 25.4% | −394.9% | −409.3% | — | — | 2 | |
| Kymera Therapeutics | FY25 | −16.7% | −891.1% | −597.6% | — | — | — | Compare |
| Wave Life Sciences | FY25 | −60.5% | −504.1% | −440.5% | — | — | — | Compare |
| Protagonist Therapeutics | FY25 | −89.4% | −343.6% | 121.9% | — | — | — | Compare |
| Septerna | FY25 | 4,174.5% | −148.6% | 238.7% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 6 | 14 | 32 | 20 | 91 | 26 | 20 | 78 | 32 | 40 |
| Revenue growth | — | 126.8% | 132.6% | −35.7% | 341.9% | −71.8% | −22.8% | 296.3% | −58.6% | 25.4% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 57 | 83 | 91 | 97 | 158 | 142 | 175 | 178 | 199 | 90 |
| Operating income | −97 | −120 | −114 | −141 | −135 | −193 | −226 | −169 | −251 | −160 |
| Net income | −97 | −120 | −110 | −134 | −116 | −192 | −220 | −153 | −237 | −160 |
| Diluted EPS (US$) | −3.02 | −2.98 | −2.33 | −2.68 | −1.98 | −2.85 | −3.21 | −2.02 | −2.88 | −1.80 |
| Diluted shares (millions) | 32 | 40 | 47 | 50 | 59 | 68 | 69 | 76 | 82 | 89 |
| Cash flow | ||||||||||
| Cash from operations | −50 | −9 | −46 | −41 | −180 | −164 | −177 | −132 | −210 | −165 |
| Capital expenditure | 4 | 2 | 5 | 6 | 7 | 8 | 4 | 5 | 9 | 1 |
| Free cash flow | −54 | −11 | −50 | −47 | −187 | −172 | −181 | −137 | −219 | −166 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 17 | 23 | 27 | 27 | 23 | 43 | 29 | 20 | 21 | 10 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 185 | 329 | 369 | 457 | 402 | 500 | 344 | 323 | 270 | 147 |
| Debt incl. finance leases | — | — | — | — | — | — | — | 0 | 57 | 59 |
| Total assets | 229 | 373 | 420 | 509 | 573 | 678 | 514 | 499 | 342 | 186 |
| Total liabilities | 95 | 165 | 184 | 246 | 179 | 124 | 154 | 150 | 207 | 159 |
| Shareholders' equity | 135 | 208 | 236 | 262 | 394 | 554 | 361 | 349 | 134 | 27 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −1,605.6% | −873.6% | −356.1% | −686.4% | −148.6% | −756.1% | −1,146.3% | −216.6% | −777.2% | −394.9% |
| Net margin | −1,605.5% | −876.5% | −344.3% | −651.4% | −127.8% | −753.6% | −1,118.3% | −196.1% | −733.7% | −395.0% |
| Free cash flow margin | −887.8% | −83.6% | −158.0% | −228.1% | −206.1% | −672.5% | −920.6% | −175.2% | −678.1% | −409.3% |
| Rule of 40 (growth + FCF margin) | — | 43.2% | −25.4% | −263.8% | 135.8% | −744.3% | −943.4% | 121.1% | −736.7% | −383.9% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −377.5% | −70.2% | −49.5% | −53.6% | −35.4% | −40.6% | −48.2% | −43.2% | −98.1% | −198.1% |
| Return on assets | −51.4% | −40.0% | −27.7% | −28.8% | −21.4% | −30.8% | −37.0% | −30.2% | −56.4% | −60.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |